Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 1, 2011, Pages 173-185

  Ramesh, Divya ^a   Ross, Gracious R ^a   Schlosburg, Joel E ^a,c   Owens, Robert A ^a   Abdullah, Rehab A ^a   Kinsey, Steven G ^a,d   Long, Jonathan Z ^c   Nomura, Daniel K ^c   Sim Selley, Laura J ^a,b   Cravatt, Benjamin F ^c   Akbarali, Hamid I ^b   Lichtman, Aron H ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 NITROPHENYL 4 [DIBENZO[D][1,3]DIOXOL 5 YL(HYDROXY)METHYL]PIPERIDINE 1 CARBOXYLATE; ACYLGLYCEROL LIPASE; ACYLGLYCEROL LIPASE INHIBITOR; ANANDAMINE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; HYDROLASE; JZL 184; N (PYRIDIN 3 YL) 4 [3 [5 (TRIFLUOROMETHYL)PYRIDIN 2 YLOXY]BENZYL]PIPERDINE 1 CARBOXAMIDE; NALOXONE; OPIATE; PF 3845; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; ENZYME INHIBITION; ILEUM; IN VITRO STUDY; IN VIVO STUDY; JUMPING; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREMOR; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACID; BEHAVIOR, ANIMAL; BENZODIOXOLES; BRAIN CHEMISTRY; DIARRHEA; ELECTRIC STIMULATION; ENDOCANNABINOIDS; HYDROLYSIS; ILEUM; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, KNOCKOUT; MONOACYLGLYCEROL LIPASES; MORPHINE DEPENDENCE; MUSCLE CONTRACTION; NALOXONE; NARCOTIC ANTAGONISTS; PIPERIDINES; PROSTAGLANDINS; PYRIDINES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROCANNABINOL; WEIGHT LOSS;

EID: 80053144160     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.181370     Document Type: Article

References (42)

1. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, Smith SE, et al. (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 16:411-420.
2. Ahn K, McKinney MK, and Cravatt BF (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 108:1687-1707. (Pubitemid 351796405)
3. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC.
4. Basilico L, Parolaro D, Colleoni M, Costa B, and Giagnoni G (1999) Cross-tolerance and convergent dependence between morphine and cannabimimetic agent WIN 55,212-2 in the guinea-pig ileum myenteric plexus. Eur J Pharmacol 376:265-271. (Pubitemid 29320152)
5. Bhargava HN (1976) Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice. Psychopharmacology (Berl) 49:267-270.
6. Birch EA (1889) The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning. Lancet 1:625.
7. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, and Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:9371-9376. (Pubitemid 32743923)
8. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, and Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fattyacid amides. Nature 384:83-87. (Pubitemid 26374593)
9. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949. (Pubitemid 23026736)
10. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, and Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99:10819-10824.
11. Dyer KR, Foster DJ, White JM, Somogyi AA, Menelaou A, and Bochner F (1999) Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther 65:685-694. (Pubitemid 29294032)
12. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 199:375-384.
13. Howlett AC and Mukhopadhyay S (2000) Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids 108:53-70.
14. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
15. Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, King AR, Redhi GH, Yasar S, Piomelli D, et al. (2008) Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry 64:930-937.
16. Kuhlman JJ Jr, Levine B, Johnson RE, Fudala PJ, and Cone EJ (1998) Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 93:549-559. (Pubitemid 28188074)
17. i/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot. Mol Pharmacol 79:461-471.
18. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavón FJ, Serrano AM, Selley DE, Parsons LH, et al. (2009a) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5:37-44.
19. Long JZ, Nomura DK, and Cravatt BF (2009b) Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 16:744-753.
20. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL, et al. (2009c) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci USA 106:20270-20275.
21. Maguma H, Thayne K, and Taylor DA (2010) Characteristics of tolerance in the guinea pig ileum produced by chronic in vivo exposure to opioid versus cannabinoid agonists. Biochem Pharmacol 80:522-532.
22. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, Bodor AL, Muccioli GG, Hu SS, Woodruff G, et al. (2010) The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 13:951-957.
23. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
24. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, and Compton DR (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90.
25. Munro S, Thomas KL, and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65. (Pubitemid 23305569)
26. Nestler EJ and Tallman JF (1988) Chronic morphine treatment increases cyclic AMP-dependent protein kinase activity in the rat locus coeruleus. Mol Pharmacol 33:127-132. (Pubitemid 18070102)
27. Pan B, Wang W, Long JZ, Sun D, Hillard CJ, Cravatt BF, and Liu QS (2009) Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl) piperidine-1- carboxylate (JZL184) enhances retrograde endocannabinoid signaling. J Pharmacol Exp Ther 331:591-597.
28. Paton WD (1957) The action of morphine and related substances on contraction and on acetylcholine output of coaxially stimulated guinea-pig ileum. Br J Pharmacol Chemother 12:119-127.
29. Punch LJ, Self DW, Nestler EJ, and Taylor JR (1997) Opposite modulation of opiate withdrawal behaviors on microinfusion of a protein kinase A inhibitor versus activator into the locus coeruleus or periaqueductal gray. J Neurosci 17:8520-8527. (Pubitemid 27461073)
30. Ross GR, Gabra BH, Dewey WL, and Akbarali HI (2008) Morphine tolerance in the mouse ileum and colon. J Pharmacol Exp Ther 327:561-572.
31. Scavone JL, Mackie K, and Van Bockstaele EJ (2010) Characterization of cannabinoid- 1 receptors in the locus coeruleus: relationship with mu-opioid receptors. Brain Res 1312:18-31.
32. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D, Booker L, Burston JJ, et al. (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13:1113-1119.
33. Schlosburg JE, Carlson BL, Ramesh D, Abdullah RA, Long JZ, Cravatt BF, and Lichtman AH (2009) Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J 11:342-352.
34. Shaw-Lutchman TZ, Barrot M, Wallace T, Gilden L, Zachariou V, Impey S, Duman RS, Storm D, and Nestler EJ (2002) Regional and cellular mapping of cAMP response element-mediated transcription during naltrexone-precipitated morphine withdrawal. J Neurosci 22:3663-3672. (Pubitemid 37465771)
35. Sim-Selley LJ, Selley DE, Vogt LJ, Childers SR, and Martin TJ (2000) Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain. J Neurosci 20:4555-4562. (Pubitemid 30396621)
36. Solinas M, Tanda G, Justinova Z, Wertheim CE, Yasar S, Piomelli D, Vadivel SK, Makriyannis A, and Goldberg SR (2007) The endogenous cannabinoid anandamide produces Δ-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther 321:370-380. (Pubitemid 46456957)
37. Sugiura T, Kobayashi Y, Oka S, and Waku K (2002) Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids 66:173-192. (Pubitemid 34743593)
38. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, and Waku K (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215:89-97.
39. Vela G, Ruiz-Gayo M, and Fuentes JA (1995) Anandamide decreases naloxoneprecipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 34:665-668.
40. Viganò D, Grazia Cascio M, Rubino T, Fezza F, Vaccani A, Di Marzo V, and Parolaro D (2003) Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology 28:1160-1167.
41. Way EL, Loh HH, and Shen FH (1969) Simultaneous quantitative assessment of morphine tolerance and physical dependence. J Pharmacol Exp Ther 167:1-8.
42. Yamaguchi T, Hagiwara Y, Tanaka H, Sugiura T, Waku K, Shoyama Y, Watanabe S, and Yamamoto T (2001) Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res 909:121-126. (Pubitemid 32710125)